<SEC-DOCUMENT>0001075880-13-000021.txt : 20130221
<SEC-HEADER>0001075880-13-000021.hdr.sgml : 20130221
<ACCEPTANCE-DATETIME>20130221165121
ACCESSION NUMBER:		0001075880-13-000021
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130221
FILED AS OF DATE:		20130221
DATE AS OF CHANGE:		20130221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13631059

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>aform6kproforma.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<HTML>
<head><title>Converted by EDGARwiz</title> </head> <body style="MARGIN-TOP:0px; FONT-SIZE:10pt; COLOR:#000000; FONT-FAMILY:Times New Roman"> <div style=WIDTH:601px> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>UNITED STATES </b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>SECURITIES AND EXCHANGE COMMISSION </b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>Washington, D.C. 20549 </b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>&nbsp;</p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; FONT-SIZE:14pt; MARGIN-BOTTOM:16px" align=center><b>Form 6-K </b></p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; FONT-SIZE:11.5pt; MARGIN-BOTTOM:14px; LINE-HEIGHT:14.4pt" align=center><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 </b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px; LINE-HEIGHT:12pt" align=left>For the month of February, 2013. </p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px; LINE-HEIGHT:12pt" align=justify>Commission File Number ________________ </p> <p style="MARGIN:0px; LINE-HEIGHT:12pt" align=center><br></p> <p style="PADDING-LEFT:56px; FONT-SIZE:20pt; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>Novogen Limited</b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center>(Translation of registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s name into English) </p> <p style=MARGIN:0px align=justify><br></p> <p style="PADDING-LEFT:56px; FONT-SIZE:12pt; MARGIN:0px" align=center>1-7 Waterloo Road, Macquarie Park, NSW, Australia</p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px; LINE-HEIGHT:12pt" align=center>(Address of principal executive office) </p> <p style="PADDING-RIGHT:71px; PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px; LINE-HEIGHT:13.55pt" align=left>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p> <table style="MARGIN-TOP:0px; FONT-SIZE:10pt" cellpadding=0 cellspacing=0> <tr height=0 style=FONT-SIZE:0px> <td width=585 /> </tr><tr> <td width=585 style=MARGIN-TOP:0px valign=top> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>&nbsp;Form 20-F<font style=FONT-FAMILY:Wingdings> </font><font style=FONT-FAMILY:Wingdings><font face=Wingdings>x</font>&nbsp;</font><font style="FONT-FAMILY:Wingdings 2">&nbsp;</font>Form 40-F<font style=FONT-FAMILY:Wingdings> </font><font face=Wingdings>o</font></p></td></tr></table> <p style="PADDING-RIGHT:71px; PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px; LINE-HEIGHT:13.55pt" align=justify><b>&nbsp;</b>&nbsp;</p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px; TEXT-INDENT:-56px; LINE-HEIGHT:12pt" align=justify>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font face=Wingdings>o</font></p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px; TEXT-INDENT:-56px; LINE-HEIGHT:12pt" align=justify><b>Note</b>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px; TEXT-INDENT:-56px; LINE-HEIGHT:12pt" align=justify>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<font face=Wingdings>o</font></p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px; TEXT-INDENT:-56px; LINE-HEIGHT:12pt" align=justify><b>Note</b>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>home country<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>), or under the rules of the home country exchange on which the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px; TEXT-INDENT:-56px; LINE-HEIGHT:12pt" align=justify>Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. &nbsp;Yes&nbsp;&nbsp;<font style="FONT-FAMILY:Wingdings 2"><font face=Wingdings>o</font>&nbsp;</font>No <font face=Wingdings>x</font></p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>If <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>yes<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)</p> <p style="MARGIN:0px; LINE-HEIGHT:12pt" align=center><br></p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>SIGNATURES </b></p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px; TEXT-INDENT:-56px; LINE-HEIGHT:12pt" align=justify><b>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf</b> by the undersigned, thereunto duly authorized. </p> <p style="PADDING-RIGHT:20px; MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px; TEXT-INDENT:-56px; LINE-HEIGHT:12pt" align=justify><b>Novogen Limited</b> (Registrant) </p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>&nbsp;</p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>(Signature) *</p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>Andrew Bursill</p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>&nbsp;</p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>Date 21 February 2013</p> <p style=MARGIN:0px align=justify><br></p> <p style="PADDING-LEFT:56px; FONT-SIZE:9pt; MARGIN:0px; TEXT-INDENT:-56px; FONT-FAMILY:ClassGarmnd BT,Times New Roman" align=justify>* Print the name and title under the signature of the signing officer.</p> <p style=MARGIN:0px align=justify><br><br></p></div></body>
<!-- EDGAR Validation Code: A64C0CAE -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>novogendemergertaximplicatio.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Converted by EDGARwiz</TITLE>
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:625.267px"><P style="margin-top:66.2px; margin-bottom:0px"><img src="novogendemergertaximplica001.jpg" alt="[novogendemergertaximplica001.jpg]" align=bottom height=70.067 width=550.067></P>
<P style="margin-top:20px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:11pt"><B>21 February 2013</B></P>
<P style="margin-top:19.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:11pt"><B>ASX RELEASE</B></P>
<P style="margin-top:28.333px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:15pt"><B>Novogen demerger</B><FONT style="font-size:3.5pt"><B> </B></FONT><B><font style='font-family:Arial Unicode MS,Times New Roman'>&#8211;</font> tax implications</B></P>
<P style="margin-top:27.8px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">The<FONT style="font-size:10.05pt"> &nbsp;</FONT>demerger<FONT style="font-size:10pt"> &nbsp;</FONT>of<FONT style="font-size:9.95pt"> &nbsp;</FONT>Novogen<FONT style="font-size:10.1pt"> &nbsp;</FONT>and<FONT style="font-size:9.9pt"> &nbsp;</FONT>MEI<FONT style="font-size:9.95pt"> &nbsp;</FONT>Pharma<FONT style="font-size:10.1pt"> &nbsp;</FONT>is<FONT style="font-size:10.05pt"> &nbsp;</FONT>now<FONT style="font-size:9.95pt"> &nbsp;</FONT>complete. &nbsp;&nbsp;IRS<FONT style="font-size:9.8pt"> &nbsp;</FONT>Form<FONT style="font-size:10pt"> &nbsp;</FONT>8937,</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">together<FONT style="font-size:9.9pt"> &nbsp;&nbsp;</FONT>with<FONT style="font-size:9.9pt"> &nbsp;&nbsp;</FONT>a<FONT style="font-size:10pt"> &nbsp;&nbsp;</FONT>report<FONT style="font-size:10pt"> &nbsp;&nbsp;</FONT>for<FONT style="font-size:9.85pt"> &nbsp;&nbsp;</FONT>all<FONT style="font-size:9.95pt"> &nbsp;&nbsp;</FONT>shareholders<FONT style="font-size:10.1pt"> &nbsp;&nbsp;</FONT>on<FONT style="font-size:9.95pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:10pt"> &nbsp;&nbsp;</FONT>tax<FONT style="font-size:9.9pt"> &nbsp;&nbsp;</FONT>implications<FONT style="font-size:9.95pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:9.9pt"> &nbsp;&nbsp;</FONT>the</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">demerger, are now available on the Novogen website<FONT style="color:#0000FF"> www.novogen.com/</FONT></P>
<P style="margin-top:40.2px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>About Novogen</B></P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Novogen<FONT style="font-size:9.05pt"> &nbsp;</FONT>Ltd<FONT style="font-size:8.85pt"> &nbsp;</FONT>is<FONT style="font-size:9pt"> &nbsp;</FONT>a<FONT style="font-size:8.75pt"> &nbsp;</FONT>public<FONT style="font-size:8.9pt"> &nbsp;</FONT>Australian<FONT style="font-size:9.05pt"> &nbsp;</FONT>biotechnology<FONT style="font-size:8.85pt"> &nbsp;</FONT>company<FONT style="font-size:8.85pt"> &nbsp;</FONT>whose<FONT style="font-size:9pt"> &nbsp;</FONT>shares<FONT style="font-size:9pt"> &nbsp;</FONT>trade</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">on &nbsp;both &nbsp;the &nbsp;Australian &nbsp;Stock &nbsp;Exchange &nbsp;(symbol &nbsp;<font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NRT<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>) &nbsp;and &nbsp;NASDAQ &nbsp;(symbol</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NVGN<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>).<FONT style="font-size:10pt"> &nbsp;&nbsp;&nbsp;&nbsp;</FONT>The &nbsp;Company &nbsp;is &nbsp;based &nbsp;in<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>Sydney,<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>Australia &nbsp;and &nbsp;is &nbsp;focused &nbsp;on &nbsp;the</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">development<FONT style="font-size:8.45pt"> &nbsp;</FONT>of<FONT style="font-size:8.3pt"> &nbsp;</FONT>a<FONT style="font-size:8.45pt"> &nbsp;</FONT>family<FONT style="font-size:8.3pt"> &nbsp;</FONT>of<FONT style="font-size:8.3pt"> &nbsp;</FONT>novel<FONT style="font-size:8.35pt"> &nbsp;</FONT>anti-cancer<FONT style="font-size:8.05pt"> &nbsp;</FONT>drugs<FONT style="font-size:8.4pt"> &nbsp;</FONT>based<FONT style="font-size:8.25pt"> &nbsp;</FONT>on<FONT style="font-size:8.45pt"> &nbsp;</FONT>super-benzopyran</P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">and <font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>stealth<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font> drug technologies. The Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s inaugural drug candidate is CS-6.</P>
<P style="margin-top:27.667px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>About CS-6</B></P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">CS-6<FONT style="font-size:8.3pt"> &nbsp;</FONT>belongs<FONT style="font-size:8.35pt"> &nbsp;</FONT>to<FONT style="font-size:8.45pt"> &nbsp;</FONT>a<FONT style="font-size:8.7pt"> &nbsp;</FONT>new<FONT style="font-size:8.55pt"> &nbsp;</FONT>class<FONT style="font-size:8.4pt"> &nbsp;</FONT>of<FONT style="font-size:8.55pt"> &nbsp;</FONT>drug<FONT style="font-size:8.3pt"> &nbsp;</FONT>candidates<FONT style="font-size:8.95pt"> &nbsp;</FONT>intended<FONT style="font-size:8.3pt"> &nbsp;</FONT>to<FONT style="font-size:8.45pt"> &nbsp;</FONT>treat<FONT style="font-size:8.5pt"> &nbsp;</FONT>most<FONT style="font-size:8.45pt"> &nbsp;</FONT>forms<FONT style="font-size:8.6pt"> &nbsp;</FONT>of</P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">cancer &nbsp;&nbsp;in &nbsp;&nbsp;a &nbsp;&nbsp;comprehensive &nbsp;&nbsp;manner, &nbsp;&nbsp;targeting &nbsp;&nbsp;both &nbsp;&nbsp;cancer &nbsp;&nbsp;cells &nbsp;&nbsp;and &nbsp;&nbsp;their</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">progenitors,<FONT style="font-size:9.65pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:9.65pt"> &nbsp;&nbsp;</FONT>cancer<FONT style="font-size:9.55pt"> &nbsp;&nbsp;</FONT>stem<FONT style="font-size:9.55pt"> &nbsp;&nbsp;</FONT>cells.<FONT style="font-size:9.85pt"> &nbsp;&nbsp;</FONT>CS-6<FONT style="font-size:9.7pt"> &nbsp;&nbsp;</FONT>shows<FONT style="font-size:9.6pt"> &nbsp;&nbsp;</FONT>broad<FONT style="font-size:9.7pt"> &nbsp;&nbsp;</FONT>anti-proliferative<FONT style="font-size:9.6pt"> &nbsp;&nbsp;</FONT>and</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">cytotoxic &nbsp;activity &nbsp;against &nbsp;human &nbsp;cancer &nbsp;cells,<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>with &nbsp;particular &nbsp;activity &nbsp;against</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">human<FONT style="font-size:8.45pt"> &nbsp;</FONT>glioblastoma<FONT style="font-size:8.45pt"> &nbsp;</FONT>cells.<FONT style="font-size:8.5pt"> &nbsp;</FONT>CS-6<FONT style="font-size:8.3pt"> &nbsp;</FONT>also<FONT style="font-size:8.4pt"> &nbsp;</FONT>has<FONT style="font-size:8.4pt"> &nbsp;</FONT>been<FONT style="font-size:8.2pt"> &nbsp;</FONT>designed<FONT style="font-size:8.25pt"> &nbsp;</FONT>deliberately<FONT style="font-size:8.25pt"> &nbsp;</FONT>to<FONT style="font-size:8.45pt"> &nbsp;</FONT>meet<FONT style="font-size:8.5pt"> &nbsp;</FONT>the</P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">major<FONT style="font-size:7.15pt"> &nbsp;</FONT>known<FONT style="font-size:7.55pt"> &nbsp;</FONT>criteria<FONT style="font-size:7.35pt"> &nbsp;</FONT>for<FONT style="font-size:7.15pt"> &nbsp;</FONT>crossing<FONT style="font-size:7.45pt"> &nbsp;</FONT>the<FONT style="font-size:7.35pt"> &nbsp;</FONT>blood-brain<FONT style="font-size:7.35pt"> &nbsp;</FONT>barrier,<FONT style="font-size:7.4pt"> &nbsp;</FONT>and<FONT style="font-size:7.2pt"> &nbsp;</FONT>for<FONT style="font-size:7.2pt"> &nbsp;</FONT>that<FONT style="font-size:7.4pt"> &nbsp;</FONT>reason<FONT style="font-size:7.35pt"> &nbsp;</FONT>is</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">being<FONT style="font-size:7.25pt"> &nbsp;</FONT>developed<FONT style="font-size:7.15pt"> &nbsp;</FONT>as<FONT style="font-size:7.35pt"> &nbsp;</FONT>a<FONT style="font-size:7.6pt"> &nbsp;</FONT>first-line<FONT style="font-size:7.4pt"> &nbsp;</FONT>for<FONT style="font-size:7.4pt"> &nbsp;</FONT>the<FONT style="font-size:7.35pt"> &nbsp;</FONT>treatment<FONT style="font-size:7.4pt"> &nbsp;</FONT>of<FONT style="font-size:7.2pt"> &nbsp;</FONT>glioblastoma<FONT style="font-size:7.35pt"> &nbsp;</FONT>multiforme,<FONT style="font-size:7.4pt"> &nbsp;</FONT>the</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">main form of primary brain cancer.</P>
<P style="margin-top:27.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>Further information</B></P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Contact Dr Graham Kelly, Chief Executive Officer.</P>
<P style="margin-top:27.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">T: &nbsp;(61 2) 9878 0088</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">M: (61) 0459 200 095</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">E: Graham.Kelly@novogen.com</P>
<P style="margin-top:23.667px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Further information is available on the Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s web site, www.novogen.com</P>
<P style="margin-top:23.667px; margin-bottom:0px"><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: 6D609F74 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>novogendemergertaximplica001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 novogendemergertaximplica001.jpg
M_]C_X``02D9)1@`!`0$```````#_X0"N17AI9@``34T`*@````@``8=I``0`
M```!````&@```````9*&``<```!Z````+`````!53DE#3T1%``!#`%(`10!!
M`%0`3P!2`#H`(`!G`&0`+0!J`'``90!G`"``=@`Q`"X`,``@`"@`=0!S`&D`
M;@!G`"``20!*`$<`(`!*`%``10!'`"``=@`V`#(`*0`L`"``<0!U`&$`;`!I
M`'0`>0`@`#T`(``Y`#``"O_^`#Q#4D5!5$]2.B!G9"UJ<&5G('8Q+C`@*'5S
M:6YG($E*1R!*4$5'('8V,BDL('%U86QI='D@/2`Y,`H`_]L`0P`(!@8'!@4(
M!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R`B+",<'"@W*2PP,30T
M-!\G.3TX,CPN,S0R_]L`0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\``$0@`@`/H
M`P$B``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*"__$
M`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R@9&A""-"
ML<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY
M^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!`@0$
M`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)R
MT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BY
MNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#`0`"
M$0,1`#\`]_HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BD)P.E-
M5MR@D8S0`^BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H-%%`#3P#6-X:U0:MH%I<DYDV
MF.7CHZ$JWZJ:V&&0:\5\$^+!X;\8ZKHE_($LKB]DV,W`BEW$<^@(`^F*J*NC
M&I5Y)*^S/;,TM-#9Q3JDV"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`3J*#14%Q=16L)EGD2-`<%G;`_.@%O8GI:IVNHVEX
M6%M<13%>6\MPV/RJWFD-IK1A2]:;GO56WU&SNW*6US#,RC)".&('X4Q6;+E%
M-W=>*0MCGM0`XT=JR[W7]*T]REUJ%M#(!G:\H!_*HK;Q5H=VVRWU2U=CT`E&
M:7,BU2FU=)FN>017S)X[L_L?CC686R0UP9>?]OYOZU],!]P!'>O"?C#8&U\8
M0W@!"7=LISGC<IVG]-OYUK2>IY^.@_9W[&U\-_B&08-"UJ8Y^Y:W+GK_`+#'
MU]#7KX;(KY#)[]_6O=OACXU;7+4Z3J$F=1M4^5R>9HQQD_[0XS^!JJD.J,L)
MB;^Y(])H--STXI<UB>D&._>BJ9U*S%R+8W,(G)P(_,&[/7I5H-[4`TUN.^M(
M>*J7FJ6=@FZ[N8H5]9'"BLY?&/AYWV+J]H6_ZZBE=(M4IR5TF;M+5>&YBN8Q
M)#(DB-T96R#4H.:9#36X^BDSQ36<`=1^=`#J.M8]UXGT6S<I<:G:QN.JF49'
MX40>*=#N6"Q:K:.QZ`2BES(T]E4M>S-FBHDD60`J00>A%.9@JEF(`'4DT&=G
M<?169_;VE=]1M!S_`,]E_P`:7^WM*/\`S$;3_O\`+_C1=%<DNQHT'%4[;4[*
M\=DMKJ&9E&2(Y`Q`_"IYIXX(FEE=(XU&69S@#\:=Q6:=B6CI5.VU.SNW*6]S
M#,PY(20,0*M[LTMP::W%I>M-)XY[54@U*SN9V@ANH))5ZHD@+#\*!)-EVBBB
MF`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%':B@T`-K
MC/B<`?!%UW^:/_T(5VE<9\3O^1)N_P#>3_T(5$_A9OA?XT?4\J\-ZI=>%=2L
M]6"_Z'<%DD"_QJ#AO^!#&:]_M;J*[MH[B!@\<BAE8'@@CBO+_#OAR/Q'\,VM
MP%6YCFE>!\?=?<?Y]*D^&7B*2WN)?#E_^[D1F\A7Z@@_,GX=1^-94VXV3/0Q
ML56YI1WCOZ'J,O\`JV'M7D/PE`'B'5&`Y,//`_OFO77)*GZ5Y'\)?^1AU3_K
MB/\`T,UI/XD<E!?N:GR/7S@=:\G\:^.;VZU%M#T-G!W^4\L0R[O_`'$_QKOO
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M?YUUGCKQF/#=NEM:[&U&=?DW=(U[N:F^'VD_V3X3MVD3;/<YGE'NW0?@H`KS
MFWC_`.$R^)LGV@E[9IV8CMY4?`'XX'_?1K"[44NK/6C&%6O*4E[L2YH/@?4_
M%^-6UJ]F2&7YD+C,CCV!X5?3BNHF^$VAM;[(YKN.0?Q^;N_\=(Q^0KO%C6-5
M"`*HZ`#BI,5:II;G-4QM5RO%V78\-O+'Q!\-]1CEM[@R6,C84@'RY/\`99?X
M6QZ5ZQX:UZV\1:/%?V_RD\21YYC?NM3:WI4&L:1=6-P-T<J$<_PGL1]#S7EW
MPNO)]/\`$]WI,K']ZC;U_P!N,XS^7\A4KW96Z,VE;%4'-KWH_B>NW5U#9VTM
MQ<2+'#$I>1VZ*HZFO']0\0Z]X]UA]-T8O;V([9V_+_>=NH^@KH_BSJCVNBVU
MA&VTW4F7Y_A7G'YX_*M3X=Z'%I7A:UG"C[1=J)I&[D$?*/P!_4T2O*7*31C&
MC1]M)7;T1BV/PBL$C4W]_<2R'DB+:BY]NI_6G7OP@TN12;2]NH6[!]KK^HS^
MM>D;:7%5[./8Q^NU[WYCE/!/AN]\.:?/!>W9N&>4E`K,41<<;0>F>?TKH-2P
M=+N1_P!,F_E5O'/7I575.-,NO^N3?RJFK(QYW.IS,\/\"^#K+Q4;[[3/-`;?
M9M\G;SNW9SD'TKLO^%/:1_T$;[_R'_\`$5G?!YUC?5MQ`SY6,\?WZ]5:6,#[
MZ_G6<(Q:/0Q>(K0JM19RWA?P)8^%[V:[MKJXF>:,1L)=N,`Y[**L^.Q_Q1.K
M#K^X/:NB#!ERN"/8USWCO_D2=6_ZX&K:2CH<5.<IUHREO<\4T*]O/#E[9ZY;
M1Y@:5H6`_P"6@&-RGWP<BOH'3;Z#4["&\M9!)#,@96'<5YKX)T*'Q#\/;^QE
M&"UT[1N!RC@*0P_&H_AWKL^BZQ/X9U+Y,RL(@3PDG=1[,.1^-94VXV7<]'&1
M5?F:^*/Y'K3C*GZ5XO\`#Y!_PL6^P!QYY''_`$T->S,P*$^U>-_#W_DHM]_V
M\?\`HRKG?F1S81+V52_8]H'2EI.U+6IP!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`(:XSXG?\`(DW7^\G_`*$*[/N*XSXG'_BB
M;K_>3_T(5$_A9T83^-'U(OA8,^#E_P"N\O\`Z%7/?$G0)=/OXO$FG9C<.OG,
M@^ZX^Z_\@:Z+X5_\B<O_`%\2_P#H1KK;RSAOK.:VN(P\4J%&4]P:E1O!&\ZS
MI8J4NES&\+^((_$6@)>(-LJ@I-&>J..H_K^-<#\)?^1@U0?],1_Z&:I:=/<_
M#WQI)8W#,;"X(4L3PT9/RO\`4$X-7/A*1_PD&IX(*F(8(_WS6?->23W.F5#D
MI5)1V=FCM/B1&TG@C4-N?E56./0,":R?A)(A\.W4>072Y;./<`BNWU2QCU+3
M+FRE'[N>-D/XBO&/"NK3>!_%4]CJ8*PN?*G/]T@_+)_NXS^=7/2:9CA_WN&E
M26^Y[I03@57BNHIXA+$ZLC#(8'@CZU*S@+DD"MCS6FG8YSQU-%!X,U1Y!E3"
M4`]R<?SKF/@_$ZZ7J4A'R-.J@^X7G^8K*^)/BA-4GCT73SYT<;@S,G.^3H$7
MUP?Z5W_@S0VT'PS;6D@`N&'F3X_OMU'X<#\*Q^*I<]*2='"<LMY,S?B#X,3Q
M3I*R6P4:E;@M`QXWCNI^OZ5\]7$,MM,\$\3Q31L4>-QAE(ZC'K7USCWKS[X@
M_#^+Q'`=1T]!%JL:>F!./[K?[7H?P^G73G;<^>Q6&YUS1W/._A/>FS\=00[L
M+=121-^6[^:UT_BMO^$J^(]EHR'=!;D)(.W]Z3_QW:/QKS30[Q]#\265Y/&\
M;V=PIEC/##!PRG]17JWPMT^2^O\`4M?NAF620HI/]XG<_P#,"L\0KR2.[*'R
M4IU'TT/3?+$=OL48`&!7C'PVD%GXZG@F&V5XY(@#_>#;B/R%>VD<'TKQ#QA8
MW7A+QNFLVBGR9I?M,9S@%C]]#[GD_0_6L*BLTST<%+F4Z?5H]NR/6G5CZ)KM
MGK^GQW=G)E6^^A^\C=PP[&M?(K5.YP2BXNS6HV0C8<^E>*>#1]H^*,LL;93S
M;E\@=L__`%Z[OQWXMAT+2GMX'#:C.A6)`>4!XWGT'IZFL#X3Z')$ESK,RL!-
M^Z@+=64<EA[$_P`JRG[TDET/1PZ=+#SG+KHBM\8(6$^ER#E=LB#Z_*:]#\-7
M"77AK39H\;6MH^G;Y1D?TK+\=Z"^O^&Y(H5S=0GS81W+`<C\1D5QWPX\816`
M&A:BPA7>?L[L<`'/*'TY]?<4?#-L+>VPJY=XGKU5KRX%K937!4L(D9\#J<#-
M2K(K=#GZ52UHYT6]'K`_\C6M]#SXQ]Y)F+X2\8Q>*UN3%:2V_P!G*@^8<YW9
M]/I6]JG_`""[K_KDW\C7FGP;(VZKTY:+^35Z5JG_`""[G_KDW\JE.\;G16IJ
MG7Y8GAO@WPI)XG:\$>H/9^1M^X"=V[=UY'I76'X37*X)\03_`/?!_P#BJA^#
MW#ZMGC_4]O\`?KU?@U%.":.O%XNK&JXIZ&7X?TMM$T6VT]YVG:%-IE88+51\
M=C_BB-5_ZX&NASV/XUSWCL_\43JH_P"F!JY+W6<%*3=:+>]S#^$G_(K7!_Z>
MW_DM4/B=X:<JGB&P!2>'`GV<'`Z/]5_E5_X2KGPM<?\`7V_\EKNIH$GA>.5%
M='&&4C((/6E&-X)'15K.EBG+S.;\&>)$\2Z`DKD"[A_=W"XQSZ_0\?K7`_#W
M_DHM]_VW_P#1AJ&1+CX<^.?DR=-N.GH8B?YK_GK4OPZ8/\0[UD(966=@?53)
MD']167-[R3.Q45"G4G'X6M#VGM2TG:EKI/%"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`H-%!H`:><US7CG2KO6O"]Q9V**\[E2H9MHX
M8'K72XHP#2:NK%4YN$E)=#EO`6D7FB>&EL[]$2<32-M5MPP374T8XZTN!0E9
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M#5\]UX?O3*G8*VQRO8,IX;%2/J'Q+N$%O]E:,]#((D4G\2:];Q04_P`XK/V?
M9G9]=;UE%-^AY5HGPQO+R^%]XENC(6;<\*N6+G_:8]O;]:]/A@CMX4BB14C0
M!551@`#M4V`*7^55&*1A6Q$ZS]YB$9%<'XL^'-IK<DEY9.EK>.<R`KF.4X_B
M'K[_`%XKO<&DV\4VDR:56=)WBSQN'3OB)X='DVAEFB'W=KK*OX!N14TC?$K5
MD:!X3%&Z[6!6-`0?SKU[:/04!1CH*S]EYLZOKSW<%?T.)^'_`(3O?#5O=M?2
M0M).5(6(D[<>I/UKK;^)YK&>-!EF0@#/4XJUBE/6K4;*QRSJRG/G>YXOI/A'
MQWH7F_V:L$'G8WXDC;.,XZCT)K3^R?%`#_CZC_.+_P")KU3`I<#VJ/9K:[.A
MXV4G=Q7W'"^%X?&T>L$Z].DECY;``%/O9&/N@>];WBNPN-3\,:A9VJ!IYH2J
M`M@9K:QS015J-E8PE6;FII)'(_#S1;[0=!FM=0C2.9KAI`%?=P0/\#77TFT4
M[%-*RLB:DW4DY/=G,>,_#*^)-$>%<"[BS)`^.C>GT/3\CVKB_AYX8UG2?$WV
MJ^LC##Y#+NW@_-D5ZT1G\J:$PV:ETTY<QM3Q4X4W3Z,D%%%%6<P4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
B444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
